Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non–small-cell lung cancer

LV Sequist, J Von Pawel, EG Garmey… - Journal of Clinical …, 2011 - ascopubs.org
Purpose c-MET (MET) receptor activation is associated with poor prognosis and epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in non–small-cell …
被引用次数：468 相关文章
[PDF] researchgate.net

[PDF][PDF] Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

LV Sequist, J von Pawel, EG Garmey, WL Akerley… - J Clin …, 2011 - researchgate.net
Methods Previously treated patients with EGFR TKI–naive advanced NSCLC were randomly
assigned to receive oral erlotinib (150 mg daily) plus oral tivantinib (360 mg twice daily) or …

Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

LV Sequist, J von Pawel, EG Garmey… - Journal of Clinical …, 2011 - cir.nii.ac.jp
< jats: sec>< jats: title> Purpose</jats: title>< jats: p> c-MET (MET) receptor activation is
associated with poor prognosis and epidermal growth factor receptor (EGFR) tyrosine …
[PDF] academia.edu

[PDF][PDF] Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

LV Sequist, J von Pawel, EG Garmey, WL Akerley… - J Clin Oncol, 2011 - academia.edu
Methods Previously treated patients with EGFR TKI–naive advanced NSCLC were randomly
assigned to receive oral erlotinib (150 mg daily) plus oral tivantinib (360 mg twice daily) or …

[引用][C] Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non-Small-Cell Lung Cancer

LV SEQUIST, J VON PAWEL… - Journal of clinical …, 2011 - pascal-francis.inist.fr
Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in
Previously Treated Non-Small-Cell Lung Cancer CNRS Inist Pascal-Francis CNRS Pascal …

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer.

LV Sequist, J von Pawel, EG Garmey… - Journal of Clinical …, 2011 - europepmc.org
Purpose c-MET (MET) receptor activation is associated with poor prognosis and epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in non-small-cell …

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer

LV Sequist, J Von Pawel… - Journal of …, 2011 - utsouthwestern.elsevierpure.com
Purpose: c-MET (MET) receptor activation is associated with poor prognosis and epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in non-small-cell …

Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer

LV Sequist, J von Pawel, EG Garmey… - Journal of clinical …, 2011 - pubmed.ncbi.nlm.nih.gov
Purpose c-MET (MET) receptor activation is associated with poor prognosis and epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) resistance in non-small-cell …

[引用][C] Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer

LV Sequist, DB Costa, EG Garmey, D Ferrari… - Journal of Clinical …, 2011 - elibrary.ru
[PDF] academia.edu

[PDF][PDF] Randomized Phase II Study of Erlotinib Plus Tivantinib Versus Erlotinib Plus Placebo in Previously Treated Non–Small-Cell Lung Cancer

LV Sequist, J von Pawel, EG Garmey, WL Akerley… - J Clin Oncol, 2011 - academia.edu
Methods Previously treated patients with EGFR TKI–naive advanced NSCLC were randomly
assigned to receive oral erlotinib (150 mg daily) plus oral tivantinib (360 mg twice daily) or …